Catherine Weiss, PhD
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey. Dr Weiss is now retired.
Original Research
Brexpiprazole in Patients With MDD and Prediabetes
August 28, 2023
Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic...
Original Research
Brexpiprazole in MDD—Metabolic Parameters and Weight
October 1, 2019
Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major...
